The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and virtually, and saw leading hemonc experts from all over the world gather to showcase the latest research in hematological malignancies.
View all videos

ASH 2022

The 64th ASH Annual Meeting and Exposition
09–13 December 2022 | New Orleans, LA / Online
VJHemOncVJHemOnc@VJHemOnc·
12h

In just a few days, we'll be at the EBMT-EHA 5th European CAR T-cell Meeting & we're excited to interview experts who will bring you the latest updates from this year's congress! 🎥

Follow us for more!

@TheEBMT @EHA_Hematology #CART23 #HemOnc #ImmunoOnc #CARTcell

Reply on Twitter 1622294446921420803Retweet on Twitter 1622294446921420803Like on Twitter 16222944469214208032View Tweet 1622294446921420803
VJHemOncVJHemOnc@VJHemOnc·
16h

Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh:

🎥: http://ow.ly/Tu7K50MH1yT

#ASH22 #Amyloidosis #BMTsm #HemOnc

Reply on Twitter 1622234024499466241Retweet on Twitter 16222340244994662411Like on Twitter 16222340244994662416View Tweet 1622234024499466241
VJHemOncVJHemOnc@VJHemOnc·
20h

🚨Missed out on our post-ASH 2022 lymphoma/CLL virtual workshop?

Don't worry! We have everything you need on-demand here:

➡️http://ow.ly/O92J50MHwSA

#LymSM #CLLsm #LeuSM #HemOnc #ImmunoOnc

Reply on Twitter 1622173489468678145Retweet on Twitter 16221734894686781451Like on Twitter 1622173489468678145View Tweet 1622173489468678145
VJHemOncVJHemOnc@VJHemOnc·
21h

🎥 @elenicelli shares some recent updates on narsoplimab for the treatment of TA-TMA.

Find out more in our exclusive interview from #ASH22:

👉http://ow.ly/pZo950MH0Ou👈

#HemOnc #ImmunoOnc

Reply on Twitter 1622158252585750529Retweet on Twitter 1622158252585750529Like on Twitter 1622158252585750529View Tweet 1622158252585750529
VJHemOncVJHemOnc@VJHemOnc·
4 Feb

Jeremy Abramson (@MGHCancerCenter) shares some insights into the importance of CAR-T therapy & bispecifics in the treatment of #DLBCL:

👉http://ow.ly/tvKz50MGqxA👈

#HemOnc #LymSM #WorldCancerDay #ImmunoOnc #CloseTheCareGap

Reply on Twitter 1621901985220902914Retweet on Twitter 16219019852209029142Like on Twitter 16219019852209029145View Tweet 1621901985220902914
Load More...

ASH 2022

The 64th ASH Annual Meeting and Exposition
09–13 December 2022 | New Orleans, LA / Online
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and virtually, and saw leading hemonc experts from all over the world gather to showcase the latest research in hematological malignancies.
View all videos
VJHemOncVJHemOnc@VJHemOnc·
12h

In just a few days, we'll be at the EBMT-EHA 5th European CAR T-cell Meeting & we're excited to interview experts who will bring you the latest updates from this year's congress! 🎥

Follow us for more!

@TheEBMT @EHA_Hematology #CART23 #HemOnc #ImmunoOnc #CARTcell

Reply on Twitter 1622294446921420803Retweet on Twitter 1622294446921420803Like on Twitter 16222944469214208032View Tweet 1622294446921420803
VJHemOncVJHemOnc@VJHemOnc·
16h

Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh:

🎥: http://ow.ly/Tu7K50MH1yT

#ASH22 #Amyloidosis #BMTsm #HemOnc

Reply on Twitter 1622234024499466241Retweet on Twitter 16222340244994662411Like on Twitter 16222340244994662416View Tweet 1622234024499466241
VJHemOncVJHemOnc@VJHemOnc·
20h

🚨Missed out on our post-ASH 2022 lymphoma/CLL virtual workshop?

Don't worry! We have everything you need on-demand here:

➡️http://ow.ly/O92J50MHwSA

#LymSM #CLLsm #LeuSM #HemOnc #ImmunoOnc

Reply on Twitter 1622173489468678145Retweet on Twitter 16221734894686781451Like on Twitter 1622173489468678145View Tweet 1622173489468678145
VJHemOncVJHemOnc@VJHemOnc·
21h

🎥 @elenicelli shares some recent updates on narsoplimab for the treatment of TA-TMA.

Find out more in our exclusive interview from #ASH22:

👉http://ow.ly/pZo950MH0Ou👈

#HemOnc #ImmunoOnc

Reply on Twitter 1622158252585750529Retweet on Twitter 1622158252585750529Like on Twitter 1622158252585750529View Tweet 1622158252585750529
VJHemOncVJHemOnc@VJHemOnc·
4 Feb

Jeremy Abramson (@MGHCancerCenter) shares some insights into the importance of CAR-T therapy & bispecifics in the treatment of #DLBCL:

👉http://ow.ly/tvKz50MGqxA👈

#HemOnc #LymSM #WorldCancerDay #ImmunoOnc #CloseTheCareGap

Reply on Twitter 1621901985220902914Retweet on Twitter 16219019852209029142Like on Twitter 16219019852209029145View Tweet 1621901985220902914
Load More...
Joint discussions Press briefs Multiple myeloma MPNs Leukemia Lymphoma Immuno-Oncology Trial Updates

Latest videos

View all
2:40
Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Harinder Gill • 10 Dec 2022
1:25
Exciting updates in essential thrombocythemia: exploring novel agents
Harinder Gill • 10 Dec 2022
1:48
Characterizing the development of MDS in patients with CLL in the era of targeted therapies
Adam Kittai • 10 Dec 2022
5:00
Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AML
Jacqueline Garcia • 12 Dec 2022

Watch videos featuring...

Irene Ghobrial
MD
Dana-Farber Cancer Institute
Ruben Mesa
MD
Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Naval Daver
MD
The University of Texas MD Anderson Cancer Center
Arnon Kater
MD, PhD
University of Amsterdam, Amsterdam, Netherlands
Nicholas Short
MD
The University of Texas MD Anderson Cancer Center
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals